Best ADC Platform Technology

Winner: LegoChem Biosciences
Runner-Up: Catalent SMARTag Technology
Shortlisted: Abzena, Ajinomoto Bio-Pharma Services, Genequantum Healthcare, WuXi XDC, Synaffix

Most Promising Clinical Candidate

Winner: Enfortumab vedotin (PADCEV) – Seagen/Astellas
Runners Up: BL-B01D1 – SystImmune, Patritumab deruxtecan - Daiichi Sankyo
Shortlisted: ARX788 – Ambrx, Datopotamabderuxtecan – AstraZeneca / Daiichi Sankyo, Farletuzumab Ecteribulin – Eisai / Bristol Myers-Squibb, Ziloveramabvedotin - Merck & Co.

Best New Drug Developer

 Winner: Exelixis
Runner Up: Duality Biologics
Shortlisted: Ambrx, Eisai, Genequantum Healthcare, Iksuda Therapeutics

Best Contract Research Organization

Winner: NJ Bio, Inc. & Charles River Laboratories
Shortlisted: Abzena, ChemExpress, Eurofins, PPD, Pharmaron, Sterling Pharma Solutions

Best Contract Manufacturing Development Organization

Winner: WuXi XDC
Runners Up: Lonza, BSP Pharmaceuticals
Shortlisted: Axplora, MilliporeSigma, Piramal Pharma Solutions

Best ADC Preclinical Publication 2022

Winner: Discovery of BT8009: A Nectin-4
Targeting Bicycle Toxin Conjugate for the Treatment of Cancer
Runner Up: Targeting LRRC15 Inhibits Metastatic Dissemination of Ovarian Cancer

Best ADC Clinical Publication 2022

Winner: Trastuzumab deruxtecan in Previously Treated HER2-Positive Breast Cancer
Runner Up: Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

Outstanding Academic Investigator Award

Winner: Nathan Tumey, Binghampton University

The George R Pettit Individual Input to the Field Award

Winner: Dr. Shanu Modi, Memorial Sloan Kettering Cancer Center

Long Standing Contribution to the Field Award

Winner: Puja Sapra